Demographics and clinical characteristics of 61 patients with VGM comparing patients with and without sinus occlusion
| Sinus Occlusion Group (n = 20) | Nonocclusion Group (n = 41) | P Valuea | |||
|---|---|---|---|---|---|
| Male/female | 9:11 | 24:17 | NS | ||
| Age at the first treatment | |||||
| Neonates (0–30 days) | 2 | 10.0% | 17 | 41.5% | <.05 |
| Infants (1–24 mo) | 13 | 65.0% | 21 | 51.2% | NS |
| Children (2–15 yr) | 5 | 25.0% | 3 | 7.3% | NS |
| Presentation | |||||
| Congestive heart failure | 3 | 15.0% | 20 | 48.8% | <.05 |
| Hydrovenous disorder | 15 | 75.0% | 12 | 29.3% | <.001 |
| Developmental delay | 5 | 25.0% | 2 | 4.9% | <.05 |
| Seizure | 3 | 15.0% | 2 | 4.9% | NS |
| Headache | 0 | 0.0% | 1 | 2.4% | NS |
| Asymptomatic | 0 | 0.0% | 9 | 22.0% | <.05 |
| Embryonic sinus | |||||
| Falcine sinus | 13 | 65.0% | 24 | 58.5% | NS |
| Occipital sinus | 14 | 70.0% | 25 | 61.0% | NS |
Note:—NS indicates not significant.
↵a P value was calculated using the Fisher exact test.